3 ms·
There was a Valtrex trial a few years ago, and the results weren't impressive. Valtrex didn't even reduce EBV titers more than placebo (table III): https://iv.
by cpncrunch 3y ago
There was a Valtrex trial a few years ago, and the results weren't impressive. Valtrex didn't even reduce EBV titers more than placebo (table III):
https://iv.iiarjournals.org/content/invivo/21/5/707.full.pdf https://iv.iiarjournals.org/content/invivo/21/5/707.full.pdf
Other trials into antivirals have been negative.
- soudiere 3y agoDiscussion is more nuanced This study screened for active vs latent on number of viruses in patients vs assumed health controls, bottom chart here is what you would evaluate Valtrex effectiveness against. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-03887-0/figures/4 https://translational-medicine.biomedcentral.com/articles/10...
- cpncrunch 3y agoI don't see any mention of Valtrex there. The point is, multiple studies have been done for antivirals in ME/CFS, and there is no difference in fatigue between arms. EBV, HHV6 and HHV6 tend to reactivate during stress, but don't typically cause symptoms. I think what we're seeing in ME/CFS is this reactivation, but it's not necessarily what is causing the problem (if it was, antivirals would help, but they don't).
- soudiere 3y agoGreat point, agreed, viral re-activation seems suspect on causality. I was suggesting to crossreference Valtrex effectiveness against the activated virii in the study I linked. If Valtrex is not effective against the reactivated cohorts, we need more falsification around antivirals <-> ME/CFS.